dc.creator | Ramos, Fernando | es |
dc.creator | Hermosín, María Lourdes | es |
dc.creator | Fuertes-Núñez, Marta | es |
dc.creator | Martínez, Pilar | es |
dc.creator | Rodriguez-Medina, Carlos | es |
dc.creator | Barrios, Manuel | es |
dc.creator | Ibáñez, Francisco | es |
dc.creator | Bernal, Teresa | es |
dc.creator | Olave, Maria Teresa | es |
dc.creator | Álvarez, Miguel Ángel | es |
dc.creator | Caballero Velázquez, Teresa | es |
dc.creator | Serrano, Josefina | es |
dc.date.accessioned | 2024-04-12T12:55:32Z | |
dc.date.available | 2024-04-12T12:55:32Z | |
dc.date.issued | 2023-11-28 | |
dc.identifier.citation | Ramos, F., Hermosín, M.L., Fuertes-Núñez, M., Martínez, P., Rodriguez-Medina, C., Barrios, M.,...,Serrano, J. (2023). Survival Outcomes and Health-Related Quality of Life in Older Adults Diagnosed with Acute Myeloid Leukemia Receiving Frontline Therapy in Daily Practice. Journal of personalized medicine, 13 (12), 1667. https://doi.org/10.3390/jpm13121667. | |
dc.identifier.issn | 2075-4426 | es |
dc.identifier.uri | https://hdl.handle.net/11441/156838 | |
dc.description.abstract | Acute myeloid leukemia has a poor prognosis in older adults, and its management is
often unclear due to its underrepresentation in clinical trials. Both overall survival (OS) and healthrelated quality-of-life (HRQoL) are key outcomes in this population, and patient-reported outcomes
may contribute to patient stratification and treatment assignment. This prospective study included
138 consecutive patients treated in daily practice with the currently available non-targeted therapies
(intensive chemotherapy [IC], attenuated chemotherapy [AC], hypomethylating agents [HMA], or
palliative care [PC]). We evaluated patients’ condition at diagnosis (Life expectancy [Lee Index for
Older Adults], Geriatric Assessment in Hematology [GAH scale], HRQoL [EQ-5D-5L questionnaire],
and fatigue [fatigue items of the QLQ-C30 scale]), OS, early death (ED), treatment tolerability (TT)
and change in HRQoL over 12 months follow-up. The median OS was 7.1 months (IC not reached,
AC 5.9, HMA 8.8, and PC 1.0). Poor risk AML category and receiving just palliative care, as well as a
higher Lee index score in the patients receiving active therapy, independently predicted a shorter OS.
The Lee Index and GAH scale were not useful for predicting TT. The white blood cell count was a
valid predictor for ED. Patients’ HRQoL remained stable during follow-up. | es |
dc.format | application/pdf | es |
dc.format.extent | 16 p. | es |
dc.language.iso | eng | es |
dc.publisher | MPDI | es |
dc.relation.ispartof | Journal of personalized medicine, 13 (12), 1667. | |
dc.rights | Atribución 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | Acute myeloid leukemia | es |
dc.subject | Elderly | es |
dc.subject | Survival | es |
dc.subject | Early death | es |
dc.subject | Health-related quality of life | es |
dc.subject | Life expectancy | es |
dc.subject | Geriatric assessment | es |
dc.subject | Fatigue | es |
dc.title | Survival Outcomes and Health-Related Quality of Life in Older Adults Diagnosed with Acute Myeloid Leukemia Receiving Frontline Therapy in Daily Practice | es |
dc.type | info:eu-repo/semantics/article | es |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Instituto de Biomedicina de Sevilla (IBIS) | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Medicina | es |
dc.relation.publisherversion | https://www.mdpi.com/2075-4426/13/12/1667 | es |
dc.identifier.doi | 10.3390/jpm13121667 | es |
dc.journaltitle | Journal of personalized medicine | es |
dc.publication.volumen | 13 | es |
dc.publication.issue | 12 | es |
dc.publication.initialPage | 1667 | es |